TrialClinical pharmacokinetics2012

A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.

Céline Verstuyft et al.PubMed ↗Publisher ↗

No numbers read from the abstract.